MC# 19-11 - A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
Disease Type(s): Myelodysplastic Syndrome
Drug Classification(s): Targeted Therapy, Immunotherapy
Molecular Target(s): TIM-3
Mechanism of Action
The mechanism of action is not fully understood at this time.
In this study, the sponsor and investigators want to learn:
- About the safety and tolerability of MBG453 in combination with Decitabine or Azacitidine.
- How much of MBG453 is absorbed into the blood and how fast it is removed when given Decitabine or Azacitidine.
- Signed informed consent must be obtained prior to participation in the study
- Age ≥ 18 years at the date of signing the informed consent form (ICF)
- Morphologically confirmed diagnosis of a myelodysplastic syndrome (MDS) based on 2016 WHO classification (Arber et al 2016) by investigator assessment with one of the following Prognostic Risk Categories, based on the International Prognostic Scoring System (IPSS-R):
- Very high
- Intermediate with at least ≥ 5% bone marrow blast
- Not eligible for intensive chemotherapy
- Not eligible for hematopoietic stem-cell transplantation (HSCT)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- Prior exposure to TIM-3 directed therapy at any time. Prior therapy with immune check point inhibitors (e.g. anti-CTLA4, anti-PD-1, anti-PD-L1, or anti-PD-L2), cancer vaccines are allowed only if the last dose of the drug was administered more than 4 months prior to randomization
- Previous treatment for higher risk MDS with chemotherapy or other antineoplastic agents including lenalidomide and hypomethylating agent (HMAs) such as decitabine or azacitidine. However, previous treatment is permitted with hydroxyurea or leukopheresis.
- History of severe hypersensitivity reactions to any ingredient of study drug(s) (azacitidine, decitabine or MGB453) or monoclonal antibodies (mAbs) and/or their excipients
- Current use or use within 14 days prior to randomization of systemic, steroid therapy (> 10 mg/day prednisone or equivalent) or any immunosuppressive therapy. Topical, inhaled, nasal, ophthalmic steroids are allowed. Replacement therapy, steroids given in the context of a transfusion are allowed and not considered a form of systemic treatment.
- Investigational treatment for MDS received within 4 weeks prior to randomization. In case of a checkpoint inhibitor: 4 months minimum prior to randomization interval is necessary to allow enrollment.
- Active autoimmune disease requiring systemic therapy (e.g.corticosteroids)
- Live vaccine administered within 30 Days prior to randomization
- Dallas, TX - Mary Crowley Cancer Research - Medical City